CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
Authors: Julia Bielanin, Wade T. Iams, Heidi Chen, Amanda Cass
Published: 2023-03-31
DOI:
10.6004/jnccn.2022.7152
Source:
Full article
Abstract
No abstract found.